Comparison of Baseline and Clinical Characteristics of Patients With GIFRS and CIFRS
| Characteristics . | Patients With GIFRS (n = 11) . | Patients With CIFRS (n = 44) . | P Value . |
|---|---|---|---|
| Age, median (range), y | 46 (38–71） | 57 (25–88) | NS |
| Male | 9 (81.8) | 23 (52.2) | NS |
| Immunocompromised factors | 0 (0.0) | 16 (36.3) | .023 |
| Type 2 diabetes mellitus | 0 | 9 | NS |
| Solid organ tumors | 0 | 5 | NS |
| Autoimmune diseases | 0 | 4 | NS |
| Cirrhosis | 0 | 1 | NS |
| Trauma or destructions of facial structures | 1 (9.1) | 7 (15.9) | NS |
| Manifestations | |||
| Nasal symptoms | 3 (27.3) | 23 (52.3) | NS |
| Ocular symptoms | 7 (63.6) | 26 (59.1) | NS |
| Ear symptoms | 2 (11.1) | 2 (4.5) | NS |
| Facial symptoms | 5 (45.5) | 24 (54.5) | NS |
| Headache or dizziness | 5 (45.5) | 29 (65.9) | NS |
| Nausea and vomiting | 0 (0.0) | 6 (13.6) | NS |
| Systematic symptoms | 0 (0.0) | 9 (20.4) | NS |
| Conscious disturbance | 0 (0.0) | 3 (6.8) | NS |
| Characteristics . | Patients With GIFRS (n = 11) . | Patients With CIFRS (n = 44) . | P Value . |
|---|---|---|---|
| Age, median (range), y | 46 (38–71） | 57 (25–88) | NS |
| Male | 9 (81.8) | 23 (52.2) | NS |
| Immunocompromised factors | 0 (0.0) | 16 (36.3) | .023 |
| Type 2 diabetes mellitus | 0 | 9 | NS |
| Solid organ tumors | 0 | 5 | NS |
| Autoimmune diseases | 0 | 4 | NS |
| Cirrhosis | 0 | 1 | NS |
| Trauma or destructions of facial structures | 1 (9.1) | 7 (15.9) | NS |
| Manifestations | |||
| Nasal symptoms | 3 (27.3) | 23 (52.3) | NS |
| Ocular symptoms | 7 (63.6) | 26 (59.1) | NS |
| Ear symptoms | 2 (11.1) | 2 (4.5) | NS |
| Facial symptoms | 5 (45.5) | 24 (54.5) | NS |
| Headache or dizziness | 5 (45.5) | 29 (65.9) | NS |
| Nausea and vomiting | 0 (0.0) | 6 (13.6) | NS |
| Systematic symptoms | 0 (0.0) | 9 (20.4) | NS |
| Conscious disturbance | 0 (0.0) | 3 (6.8) | NS |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CIFRS, chronic invasive fungal rhinosinusitis; GIFRS, granulomatous invasive fungal rhinosinusitis; NS, no significance.
Comparison of Baseline and Clinical Characteristics of Patients With GIFRS and CIFRS
| Characteristics . | Patients With GIFRS (n = 11) . | Patients With CIFRS (n = 44) . | P Value . |
|---|---|---|---|
| Age, median (range), y | 46 (38–71） | 57 (25–88) | NS |
| Male | 9 (81.8) | 23 (52.2) | NS |
| Immunocompromised factors | 0 (0.0) | 16 (36.3) | .023 |
| Type 2 diabetes mellitus | 0 | 9 | NS |
| Solid organ tumors | 0 | 5 | NS |
| Autoimmune diseases | 0 | 4 | NS |
| Cirrhosis | 0 | 1 | NS |
| Trauma or destructions of facial structures | 1 (9.1) | 7 (15.9) | NS |
| Manifestations | |||
| Nasal symptoms | 3 (27.3) | 23 (52.3) | NS |
| Ocular symptoms | 7 (63.6) | 26 (59.1) | NS |
| Ear symptoms | 2 (11.1) | 2 (4.5) | NS |
| Facial symptoms | 5 (45.5) | 24 (54.5) | NS |
| Headache or dizziness | 5 (45.5) | 29 (65.9) | NS |
| Nausea and vomiting | 0 (0.0) | 6 (13.6) | NS |
| Systematic symptoms | 0 (0.0) | 9 (20.4) | NS |
| Conscious disturbance | 0 (0.0) | 3 (6.8) | NS |
| Characteristics . | Patients With GIFRS (n = 11) . | Patients With CIFRS (n = 44) . | P Value . |
|---|---|---|---|
| Age, median (range), y | 46 (38–71） | 57 (25–88) | NS |
| Male | 9 (81.8) | 23 (52.2) | NS |
| Immunocompromised factors | 0 (0.0) | 16 (36.3) | .023 |
| Type 2 diabetes mellitus | 0 | 9 | NS |
| Solid organ tumors | 0 | 5 | NS |
| Autoimmune diseases | 0 | 4 | NS |
| Cirrhosis | 0 | 1 | NS |
| Trauma or destructions of facial structures | 1 (9.1) | 7 (15.9) | NS |
| Manifestations | |||
| Nasal symptoms | 3 (27.3) | 23 (52.3) | NS |
| Ocular symptoms | 7 (63.6) | 26 (59.1) | NS |
| Ear symptoms | 2 (11.1) | 2 (4.5) | NS |
| Facial symptoms | 5 (45.5) | 24 (54.5) | NS |
| Headache or dizziness | 5 (45.5) | 29 (65.9) | NS |
| Nausea and vomiting | 0 (0.0) | 6 (13.6) | NS |
| Systematic symptoms | 0 (0.0) | 9 (20.4) | NS |
| Conscious disturbance | 0 (0.0) | 3 (6.8) | NS |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CIFRS, chronic invasive fungal rhinosinusitis; GIFRS, granulomatous invasive fungal rhinosinusitis; NS, no significance.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
